|Assessment Status||Rapid Review Complete|
|Indication||In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.|
|Rapid review commissioned||05/05/2017|
|Rapid review completed||18/05/2017|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.